| 1.3 -0.03 (-2.26%) | 05-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.64 | 1-year : | 1.92 |
| Resists | First : | 1.4 | Second : | 1.64 |
| Pivot price | 1.29 | |||
| Supports | First : | 1.21 | Second : | 1.1 |
| MAs | MA(5) : | 1.3  |
MA(20) : | 1.28  |
| MA(100) : | 1.69 |
MA(250) : | 4.03 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 65.1 |
D(3) : | 57.9 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 9.89 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DRMA ] has closed below upper band by 47.0%. Bollinger Bands are 75.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 36 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.37 - 1.38 | 1.38 - 1.38 |
| Low: | 1.28 - 1.29 | 1.29 - 1.3 |
| Close: | 1.29 - 1.3 | 1.3 - 1.31 |
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Fri, 24 Apr 2026
Dermata Therapeutics, Inc. - Common Stock (NQ: DRMA - FinancialContent
Wed, 22 Apr 2026
Dermata (DRMA) Stock Valuation | Dermata Therapeutics posts narrower loss, 3.2 pct EPS beat - - Cổng thông tin điện tử Tỉnh Sơn La
Wed, 22 Apr 2026
Bigger Capital now holds 75,200 shares after sales (NASDAQ: DRMA) - Stock Titan
Fri, 17 Apr 2026
Dermata Therapeutics (NASDAQ: DRMA) seeks approval for warrants and equity plan at 2026 meeting - Stock Titan
Thu, 26 Mar 2026
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 - Yahoo Finance
Fri, 20 Mar 2026
Dermata Gears Up For First Once-Weekly Acne Kit Launch, Eyeing A Slice Of $3.8B Market - RTTNews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 24.8 (%) |
| Held by Institutions | 5.8 (%) |
| Shares Short | 200 (K) |
| Shares Short P.Month | 44 (K) |
| EPS | -8.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.33 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -85.3 % |
| Return on Equity (ttm) | -194.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.16 |
| PEG Ratio | 0 |
| Price to Book value | 0.55 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|